Medline (MDLN) Fundamental Analysis: Revenue, Earnings & Valuation

9.55 / 10

Outperform

Fundamental analysis yields a 9.55 score, driven by top‑ranked Profit‑MV, ROE, and diluted ROE factors. Cash‑UP and Asset‑MV are weaker, dragging the asset‑value metric. Overall, the company’s profitability and return ratios are excellent, supporting an Outperform rating.

Analysis Checks(8/10)

ROA (%)

Value3.11

Score2/3

Weight12.88%

1M Return0.63%

Annualized return on equity (%)

Value8.50

Score3/3

Weight36.23%

1M Return1.64%

Profit-MV

Value0.17

Score2/3

Weight71.59%

1M Return3.26%

Cash-UP

Value-1.06

Score2/3

Weight-65.29%

1M Return-3.92%

Annualized net profit margin on total assets (%)

Value3.11

Score2/3

Weight12.88%

1M Return0.63%

ROE (diluted) (%)

Value10.79

Score3/3

Weight30.36%

1M Return1.39%

Asset-MV

Value-0.55

Score0/3

Weight-57.36%

1M Return-3.34%

ROE (%)

Value8.50

Score3/3

Weight36.23%

1M Return1.64%

Cash-MV

Value-1.45

Score3/3

Weight62.10%

1M Return2.65%

Net profit / Total profit (%)

Value92.71

Score1/3

Weight-39.62%

1M Return-2.37%

Is MDLN undervalued or overvalued?

MDLN scores 9.55/10 on fundamentals and holds a Discounted valuation at present. Backed by its 6.47% ROE, 4.07% net margin, 48.37 P/E ratio, 2.91 P/B ratio, and 0.00% earnings growth, these metrics solidify its Outperform investment rating.